Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
Pruritus continues to be a significant comorbidity in patients with chronic cholestatic liver diseases and may be exacerbated by certain bile acid-related drugs.
Read More
